INV-347 / Novo Nordisk - LARVOL DELTA

INV-347, a next generation cannabinoid receptor 1 inverse agonist, promotes body weight loss in obese mice (EASD 2025) - "These results suggest that the weight loss actions of INV-347 involve suppression of food intake as well as an increase in energy expenditure and may result from a preferential effect on VAT. While experiments to further assess the molecular mechanism are still needed, our study demonstrates the ability of INV-347 to greatly improve metabolic outcomes in obese mice."

Preclinical • Metabolic Disorders • Obesity

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 (clinicaltrials.gov) - P1 | N=91 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

Phase 1 trial with INV-347 completed and development terminated (GlobeNewswire) - P1 | N=NA | "In May 2025, Novo Nordisk completed a phase 1 trial with INV-347, a next-generation oral small molecule CB1 receptor blocker. The trial investigated the safety, tolerability and pharmacokinetics of INV-347 administered once daily to participants with normal weight or overweight/obesity at both single and multiple ascending doses for up to 28 days. In the trial, INV-347 appeared to have a safe and well-tolerated profile. Following completion of the trial, Novo Nordisk has terminated further development of INV-347 due to the pharmacokinetic profile and portfolio considerations."

Discontinued • P1 data • Trial completion • Obesity